The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor compound, alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://e-bookmarks.com/story7409373/retatrutide-and-nicotinamide-adenine-dinucleotide-a-triple-threat-strategy-to-physiological-health